Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/12/2025

Lipid Management

Patient Selection

  • Patients with established cardiovascular disease or familial hypercholesterolemia who are on maximally tolerated statin therapy plus ezetimibe but still have LDL-C levels ≥70 mg/dL should be considered for PCSK9 inhibitors, as recommended by the American Diabetes Association 1, 2
  • Patients with established atherosclerotic cardiovascular disease (ASCVD) and LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe should be considered for PCSK9 inhibitors 2
  • Heterozygous familial hypercholesterolemia (HeFH) patients with LDL-C ≥100 mg/dL despite maximally tolerated statin plus ezetimibe should be considered for PCSK9 inhibitors 3
  • Very high-risk patients with clinical ASCVD who are on maximally tolerated statin therapy with LDL-C ≥70 mg/dL should be considered for ezetimibe, as recommended by the American College of Cardiology 4, 5

Treatment Approach

  • High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is recommended as first-line therapy by the American College of Cardiology 1
  • Ezetimibe 10 mg daily should be added as second-line therapy if LDL-C remains ≥70 mg/dL 2
  • PCSK9 inhibitors should be added as third-line therapy if LDL-C remains ≥70 mg/dL (for ASCVD) or ≥100 mg/dL (for FH) despite maximally tolerated statin plus ezetimibe 1, 2
  • The standard dose of ezetimibe is 10 mg orally once daily, with or without food 5, 6, 7
  • Ezetimibe can be administered with bile acid sequestrants, but should be given either ≥2 hours before or ≥4 hours after the bile acid sequestrant 5, 6, 7

Efficacy and Safety

  • PCSK9 inhibitors can reduce LDL-C by 50-60% beyond statin therapy 1
  • The FOURIER trial (evolocumab) showed a 15% relative risk reduction in major cardiovascular events, and a 20% reduction in composite of cardiovascular death, MI, or stroke 2
  • The ODYSSEY OUTCOMES trial (alirocumab) showed a 15% reduction in adverse cardiovascular events 8
  • PCSK9 inhibitors are generally well-tolerated with minimal side effects, and the most common adverse effects are injection site reactions 9
  • Ezetimibe provides an additional 15-20% reduction in LDL-C, and reduces composite cardiovascular endpoints by 2.0 percentage points (absolute risk reduction) in patients with recent acute coronary syndrome 5, 6
  • Ezetimibe has a safety profile similar to placebo when used as monotherapy, with minimal systemic absorption resulting in few drug interactions, making it suitable for elderly patients on multiple medications 5, 6, 7

Monitoring and Follow-up

  • LDL-C should be measured 4-12 weeks after initiating therapy, and non-HDL-C levels should be monitored based on individual risk factors 4, 5
  • Initial assessment should include measuring LDL-C 4-12 weeks after initiating therapy, and ongoing monitoring should continue to track LDL-C and non-HDL-C levels based on individual risk factors 5, 6, 7
  • The American Heart Association recommends monitoring non-HDL-C in patients with triglycerides ≥200 mg/dL and treating to target, and LDL-C and non-HDL-C levels should be monitored in patients receiving ezetimibe therapy, with treatment goals based on individual patient risk factors 10

Cost Considerations

  • Ezetimibe is substantially less expensive than PCSK9 inhibitors and should be tried before considering these agents, according to the Mayo Clinic Proceedings and the British Medical Journal 5, 6, 7, 11, 12, 13
  • Cost considerations should favor ezetimibe over PCSK9 inhibitors, as ezetimibe is substantially less expensive and should be tried before considering PCSK9 inhibitors 5, 6, 7

Target LDL-C Levels

  • The European Heart Journal recommends a target LDL-C <55 mg/dL (1.4 mmol/L) for very high-risk patients on high-intensity statin therapy 12, 14
  • The American College of Cardiology recommends adding ezetimibe to maximally tolerated statin therapy as a first-line adjunctive therapy in patients with very high cardiovascular risk whose LDL-C remains ≥70 mg/dL despite statin therapy, with a strong recommendation (Class I) based on evidence from the IMPROVE-IT trial 5, 6

REFERENCES